Top Markets
Coin of the day
NuCana plc NuCana plc

NuCana plc

NCNA
Clasificación en acciones #32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Precio por acción
$1.56
Capitalización bursátil
$9.44M
Cambio (1 día)
-2.20%
Cambio (1 año)
-58.31%
País
GB
Comercio NuCana plc (NCNA)

Categoría

Historial del precio de la acción de NuCana plc (NCNA)
Precio más alto de cierre: $1.47 el 2026-08-01

Precio más bajo de cierre: $86.30K el 2017-09-01
Historial del precio de la acción de NuCana plc desde 2017 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2026 (TTM) -26.46%
2025 -98.52%
2024 -85.03%
2023 -55.23%
2022 -68.92%
2021 -46.94%
2020 -31.87%
2019 -57.91%
2018 45.00%
2017 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$515.82 31.32%
US
$991.05 51.58%
NL
$736.64 7.19%
CH
$1.07K -6.40%
KR
$255.50 13.38%
BE